{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:14:05Z","timestamp":1789150445045,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2016.00243","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T14:44:17Z","timestamp":1479739457000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine"],"prefix":"10.3389","volume":"6","author":[{"given":"Amit","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykhaylo","family":"Morgunskyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Belagali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Prasad","family":"Akku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"India and Ukraine Haemato-oncology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic advancements in multiple myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front Oncol"},{"key":"B2","author":"National Cancer Registry of Ukraine"},{"key":"B3","article-title":"Multiple myeloma \u2013 the Indian perspectives: current situation [abstract]","volume-title":"Continuing Medical Education Congress","author":"Kumar","year":"2016"},{"issue":"2","key":"B4","first-page":"S45","article-title":"Evolving strategies for the management of multiple myeloma: a managed care perspective","volume":"20","author":"Klein","year":"2014","journal-title":"Am J Manag Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e573603","DOI":"10.3747\/co.21.1798","article-title":"Bortezomib in multiple myeloma: systematic review and clinical considerations","volume":"21","author":"Kouroukis","year":"2014","journal-title":"Curr Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4137\/CMO.S7764","article-title":"Efficacy of bortezomib as first-line treatment for patients with multiple myeloma","volume":"7","author":"Painuly","year":"2013","journal-title":"Clin Med Insights Oncol"},{"issue":"4","key":"B7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines\u00ae insights multiple myeloma, Version 3.2016. Featured updates to the NCCN guidelines","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","author":"The British Committee for Standards in Hematology (BCSH)","journal-title":"2016 Guideline"},{"key":"B9","author":"European Society for Medical Oncology (ESMO)","journal-title":"2016 Guidelines"},{"key":"B10","journal-title":"Adapted Clinical Guideline. Diagnosis and Treatment of Multiple Myeloma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM2005\u201301 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9758","key":"B13","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of proteasome inhibition for extending remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"B19","journal-title":"Unified Clinical Protocol of Primary Secondary (Specialized) and Tertiary (Highly Specialized) Medical Care. Multiple Myeloma"},{"key":"B20","journal-title":"Myeloma in India: CureTalk in Conversation with Dr. Lalit Kumar, Professor of Medical Oncology, All India Institute of Medical Sciences (AIIMS), Delhi, India"},{"key":"B21","author":"Centre for International Blood and Marrow Transplant Research (CIBMTR)","journal-title":"Data"},{"key":"B22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4103\/0019-509X.178388","article-title":"Bortezomib in newly diagnosed patients with multiple myeloma: a retrospective analysis from a tertiary care center in India","volume":"52","author":"Pragnya","year":"2015","journal-title":"Indian J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.18553\/jmcp.2008.14.S7-A.19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"Cook","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"B24","volume-title":"Economic Evaluations of Targeted therapy and Risk-Stratified Treatment Approaches in Multiple Myeloma [Dissertation]","author":"Gaultney","year":"2014"},{"key":"B25","volume-title":"Access to Cancer Treatment. A Study of Medicine Pricing Issues with Recommendations for Improving Access to Cancer Medication: A Report","author":"\u2018t Hoen","year":"2015"},{"key":"B26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMp1113112","article-title":"Generic atorvastatin and health care costs","volume":"366","author":"Jackevicius","year":"2012","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","article-title":"The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"issue":"9","key":"B28","first-page":"52","article-title":"Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma","volume":"17","author":"Mehta","year":"2004","journal-title":"Manag Care Interface"},{"key":"B29","first-page":"73","volume-title":"Costs of Treating Lymphoproliferative Disorders in Ukraine: a Pilot Evaluation (Special Issue)","author":"Mandrik","year":"2012"},{"issue":"7","key":"B30","doi-asserted-by":"publisher","first-page":"A444","DOI":"10.1016\/j.jval.2011.08.1158","article-title":"PCN57 cost of treatment of multiple myeloma in Ukraine","volume":"14","author":"Mandrik","year":"2011","journal-title":"Value in Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2016.00243\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:05:54Z","timestamp":1498363554000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2016.00243\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.3389\/fonc.2016.00243","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}